Healthcare >> CEO Interviews >> October 25, 2004
HENRY L. NORDHOFF joined Gen-Probe Incorporated in July 1994 as
President and CEO. Following the spinoff from Chugai Pharmaceutical Co.,
Ltd. in September 2002, he was also appointed Chairman by the Board of
Directors. Before joining Gen-Probe, Mr. Nordhoff served as President
and CEO of TargeTech, Inc., a gene therapy company focused on the
potential treatment of inherited diseases, which was merged into the
Immune Response Corporation in 1992. Previously, Mr. Nordhoff spent over
16 years at Pfizer Inc. where he held several senior positions in
Brussels, Seoul, Tokyo and New York. Mr. Nordhoff serves on the Board of
Directors of AdvaMED, BIOCOM/San Diego, Molecular Light Technology in
Cardiff, Wales, San Diego Economic Development Corporation, UCSD Cancer
Center, California Healthcare Institute and the Board of Trustees of the
University of San Diego. He received his BA in International Relations
and Political Economy from the Johns Hopkins University and his MBA in
International Business and Finance from Columbia University. Profile
Mr. Nordhoff: Gen-Probe was founded in 1983, based on a new technology
called ribosomal RNA, which, in a nutshell,
